FIELD: biotechnology.
SUBSTANCE: present invention relates to oxyntomodulin conjugates, and can be used in medicine for preventing or treating obesity. Conjugate is capable of activating receptors GLP-1 (glucagon-like peptide-1) and glucagon and contains an oxyntomodulin derivative, Fc-region of immunoglobulin and polyethylene glycol, where polyethylene glycol covalently binds oxyntomodulin derivative with Fc-region of immunoglobulin.
EFFECT: invention provides reduced food intake, suppressing gastric emptying and promotes lipolysis with no side effects unlike native oxyntomodulin, and also demonstrates enhanced receptor-activating effects and long-term resistance as compared to native oxyntomodulin.
23 cl, 13 dwg, 3 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR TREATING HYPERLIPIDEMIA CONTAINING AN OXYNTOMODULIN DERIVATIVE | 2013 |
|
RU2768853C1 |
| NOVEL OXYNTOMODULIN DERIVATIVES AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM FOR TREATING OBESITY | 2012 |
|
RU2739209C2 |
| INSULIN ANALOGUE COMPLEX WITH REDUCED AFFINITY TO INSULIN RECEPTOR AND ITS USE | 2018 |
|
RU2779462C2 |
| IGG4 Fc FRAGMENT CONTAINING A MODIFIED HINGE REGION | 2014 |
|
RU2800558C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON | 2019 |
|
RU2823246C2 |
| ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
| EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IgE Fc RECEPTOR, A PHARMACEUTICAL COMPOSITION CONTAINING IT AND A METHOD FOR ITS PRODUCTION | 2019 |
|
RU2796162C2 |
| PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS, LIVER FIBROSIS AND LIVER CIRRHOSIS, INCLUDING FUSION PROTEINS | 2017 |
|
RU2795548C2 |
| IMPROVED FVIII FUSION PROTEIN AND ITS USE | 2019 |
|
RU2789085C2 |
| IMPROVED FACTOR IX FUNCTION PROTEIN AND ITS CONJUGATE AND THEIR USE | 2020 |
|
RU2794350C1 |
